Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression. YLHIV in the southern United States have particularly poor care engagement outcomes. South Carolina is one of nine states identified as "key drivers" of the US HIV epidemic, and HIV rates for youth in South Carolina have risen in recent years. Tailored interventions are urgently needed to improve outcomes for this population. One promising approach is to reach YLHIV via mobile Health (mHealth) technology, yet few efforts have sought to tailor mHealth interventions to the needs of YLHIV in the southern US. Thus, the scientific objective of this study is to pilot test a new mHealth intervention, called MindBodyU, designed to increase engagement/retention in care and ART adherence among YLHIV in South Carolina. In this study, investigators will evaluate the feasibility, acceptability, and initial efficacy of the mHealth intervention with a six-month pilot trial with 40 YLHIV in South Carolina.
Age range
16 Years – 25 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Study Retention
Timeframe: From enrollment to 12-weeks
Acceptability of the MindBodyU Intervention
Timeframe: From enrollment to 12-weeks
Adherence to Antiretroviral Therapy (ART)
Timeframe: From enrollment to 12-weeks; follow-up at 6-months
Viral Suppression
Timeframe: From enrollment to 12-weeks; follow-up at 6-months
HIV Care Engagement
Timeframe: From enrollment to 12-weeks; follow-up at 6-months
App engagement
Timeframe: From enrollment to 12-weeks
Perceived Burden of the MindBodyU App
Timeframe: From enrollment to 12-weeks
Perceived Feasibility of the MindBodyU App
Timeframe: From enrollment to 12-weeks